Natixis Advisors LLC Buys 1,840 Shares of Revvity, Inc. (NYSE:RVTY)

Natixis Advisors LLC increased its stake in shares of Revvity, Inc. (NYSE:RVTY) by 14.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 14,339 shares of the company’s stock after buying an additional 1,840 shares during the period. Natixis Advisors LLC’s holdings in Revvity were worth $1,600,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Janus Henderson Group PLC increased its holdings in shares of Revvity by 1.7% in the third quarter. Janus Henderson Group PLC now owns 6,335,302 shares of the company’s stock worth $809,332,000 after purchasing an additional 108,401 shares during the period. State Street Corp increased its stake in Revvity by 0.3% in the 3rd quarter. State Street Corp now owns 5,180,169 shares of the company’s stock worth $661,767,000 after acquiring an additional 17,832 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Revvity by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 2,863,793 shares of the company’s stock valued at $364,569,000 after acquiring an additional 25,078 shares in the last quarter. EdgePoint Investment Group Inc. boosted its position in shares of Revvity by 34.6% during the 3rd quarter. EdgePoint Investment Group Inc. now owns 2,685,775 shares of the company’s stock valued at $343,108,000 after acquiring an additional 690,534 shares during the last quarter. Finally, RGM Capital LLC grew its holdings in shares of Revvity by 3.2% during the third quarter. RGM Capital LLC now owns 980,858 shares of the company’s stock worth $125,305,000 after purchasing an additional 30,000 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Price Performance

RVTY opened at $108.60 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03. The stock’s 50 day simple moving average is $116.15 and its 200 day simple moving average is $117.48. The firm has a market cap of $13.05 billion, a price-to-earnings ratio of 49.14, a PEG ratio of 3.82 and a beta of 1.06. Revvity, Inc. has a 1 year low of $97.32 and a 1 year high of $129.50.

Revvity (NYSE:RVTY) last issued its earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same period in the prior year, the business earned $1.25 EPS. As a group, analysts predict that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be issued a dividend of $0.07 per share. The ex-dividend date is Thursday, April 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.26%. Revvity’s dividend payout ratio is currently 12.67%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on RVTY shares. Barclays lifted their target price on shares of Revvity from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Bank of America raised shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price objective for the company in a report on Friday, December 13th. Raymond James reissued an “outperform” rating and issued a $145.00 target price (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. KeyCorp lifted their price target on Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Finally, Sanford C. Bernstein lowered Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price objective on the stock. in a research report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $136.25.

Insider Transactions at Revvity

In related news, insider Joel S. Goldberg sold 15,170 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the sale, the insider now owns 33,400 shares of the company’s stock, valued at $4,232,782. This trade represents a 31.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Tajinder S. Vohra sold 5,492 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the transaction, the insider now directly owns 19,652 shares in the company, valued at approximately $2,295,550.12. The trade was a 21.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by company insiders.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.